Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Gain Therapeutics (GANX) over the last 4 years, with Q3 2025 value amounting to $24568.0.

  • Gain Therapeutics' Treasury Shares fell 7607.84% to $24568.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $24568.0, marking a year-over-year decrease of 7607.84%. This contributed to the annual value of $102702.0 for FY2024, which is 7920.17% down from last year.
  • Per Gain Therapeutics' latest filing, its Treasury Shares stood at $24568.0 for Q3 2025, which was down 7607.84% from $28833.0 recorded in Q2 2025.
  • Gain Therapeutics' Treasury Shares' 5-year high stood at $598150.0 during Q2 2023, with a 5-year trough of $24568.0 in Q3 2025.
  • Its 4-year average for Treasury Shares is $253685.8, with a median of $212089.5 in 2023.
  • In the last 5 years, Gain Therapeutics' Treasury Shares skyrocketed by 6294.31% in 2023 and then tumbled by 7971.07% in 2024.
  • Over the past 4 years, Gain Therapeutics' Treasury Shares (Quarter) stood at $303050.0 in 2022, then surged by 62.94% to $493799.0 in 2023, then tumbled by 79.2% to $102702.0 in 2024, then plummeted by 76.08% to $24568.0 in 2025.
  • Its last three reported values are $24568.0 in Q3 2025, $28833.0 for Q2 2025, and $91149.0 during Q1 2025.